Navigation Links
BioMS Medical to present at Jefferies Healthcare Conference
Date:6/18/2008

Toronto Stock Exchange Symbol: MS

EDMONTON, June 18 /PRNewswire-FirstCall/ - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that Mr. Kevin Giese, President and CEO, will present at the Jefferies 2nd Annual Healthcare Conference in New York.

WHEN: Wednesday June 25th at 3:45 pm (EDT)

WHERE: Mandarin Oriental, New York

About the Jefferies 2nd Annual Healthcare Conference

Jefferies will host its 2nd Annual Healthcare Conference in New York City on June 24-26, 2008 which will showcase a diverse group of companies and industry experts in the areas of biotechnology, CROs, healthcare facilities & services, healthcare IT services, medical devices & diagnostics, pharmaceutical services and specialty pharmaceuticals. The conference will be organized by sector focus and will include public and private company presentations and investor meetings.

About BioMS Medical Corp.

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, MBP8298 (dirucotide), is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for secondary progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. It additionally is being evaluated for relapsing remitting MS patients in a Phase II trial in Europe entitled MINDSET-01. In December 2007, BioMS entered into a licensing and development agreement granting Eli Lilly and Company exclusive worldwide rights to MBP8298 (dirucotide) in exchange for an $87 million upfront payment, milestone payments and escalating royalties on sales. For further information please visit our website at http://www.biomsmedical.com.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that MBP8298 will continue to demonstrate a satisfactory safety profile in ongoing and future clinical trials; and that BioMS Medical Corp. will complete the respective clinical trials within the timelines communicated in this release. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. BioMS Medical announces its intention to renew a normal course issuer bid
2. BioMS Medical to present at BioContact 2007
3. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
4. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
5. BioMS Medical announces third quarter 2007 results
6. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
7. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
9. BioMS Medical to present at BIO CEO & Investor Conference
10. BioMS Medical Announces 2007 Year End Results
11. BioMS Medical to present at BioCentury Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... ... April 27, 2016 , ... ... PET (Positron Emission Tomography) and MRI (Magnetic Resonance Imaging) in existing third-party MRI ... testing novel treatments in small animal subjects. Simultaneous PET/MRI imaging offers a solution ...
(Date:4/26/2016)... ANGELES, Calif. (PRWEB) , ... April 27, 2016 ... ... Angeles office of Lewis Roca Rothgerber Christie LLP as an associate in the ... prosecuting U.S. and international electrical, mechanical and electromechanical patent applications. He has an ...
(Date:4/26/2016)... (PRWEB) , ... April 26, 2016 , ... This unique ... Scottsdale and will offer attendees an opportunity to get the lowdown on female fertility ... Over cocktails and appetizers, Dr. Jesse Hade, of Boston IVF - The Arizona Center, ...
(Date:4/26/2016)... , ... April 26, 2016 , ... ... announced the opening of its first round of pre-proposal competition for scientific grants. ... organization seeks to identify ideas with the highest potential to replace paradigms that ...
Breaking Biology Technology:
(Date:4/26/2016)... , April 27, 2016 ... the  "Global Multi-modal Biometrics Market 2016-2020"  report to ... ) , The analysts forecast the ... CAGR of 15.49% during the period 2016-2020.  ... number of sectors such as the healthcare, BFSI, ...
(Date:4/14/2016)... Israel , April 14, 2016 ... Authentication and Malware Detection, today announced the appointment of ... assumed the new role. Goldwerger,s leadership appointment ... on the heels of the deployment of its platform ... BioCatch,s behavioral biometric technology, which discerns unique cognitive and ...
(Date:3/29/2016)... 29, 2016 LegacyXChange, Inc. (OTC: ... and SelectaDNA/CSI Protect are pleased to announce our successful ... a variety of writing instruments, ensuring athletes signatures against ... collectibles from athletes on LegacyXChange will be assured of ... DNA. Bill Bollander , CEO states, ...
Breaking Biology News(10 mins):